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ABSTRACT
A specific radioimmunoassay (RIA) for human interleukin-1 a (IL-1a) 
which detects less than 25-50 pg/ml IL-1a is described. Although human 
IL-1 a shares structural homology, receptors and multiple biological 
properties with IL-16, this RIA does not detect human IL-13 or other 
human cytokines. We recovered nearly 100% of IL-1 a added to fresh human 
heparinized blood or freshly voided urine; in contrast, using a specific RIA 
for IL-1 Í3, recovery of IL-113 added to fresh blood is approximately 50% 
reduced by nonspecific factors. In the present study, we employed this R!A 
to measure the amount of total (extracellular and cell-associated) 
immunoreactive IL-1 a produced by human blood mononuclear cells 
stimulated in vitro by different concentrations of endotoxin. Using 
ultrafiltered culture medium to reduce endotoxin content, there was no 
detectable (less than 50 pg/ml) IL-1 a produced after 24 hours. Endotoxin 
(0.5 ng/ml) induced a mean concentration of 900 pg/ml (range 180-1660 
pg/ml). At higher- concentrations of endotoxin (500 ng/ml), a mean of 
6,990 pg/ml (range 415-11,900 pg/ml) was produced. These levels were 
comparable to the amount of IL-1 B produced under similar culture 
conditions. The results indicate that IL-1 a can be measured independently 
of IL-113 in human body fluids and from human mononuclear cells.
INTRODUCTION
Polypeptide products of mononuclear macrophages are important 
mediators of the host responses to infection, inflammation or 
Immunological challenge. Cell culture assays and animal models
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demonstrate many overlapping biological activities of these cytokines 
including fever, T cell activation, induction of liver acute phase protein 
synthesis, osteoclast activation, chemotaxis, catabolic effects on 
muscles and connective tissue remodelling (reviewed in 1). Because of 
these multiple effects, the proteins were named according to their 
predominant activity: for example, endogenous pyrogen, leukocyte 
endogenous mediator, lymphocyte activating factor, osteoclast activating 
factor catabolin and hemopoietin-1 (2). Active cytokines had a molecular 
weight of 12-17 kD and further purification suggested that the various 
effects were caused by a small group of related proteins rather than many 
different molecules. Today these include tumor necrosis factor (TNF) and 
interleukin-6.
In 1979 the term interleukin-1 (IL-1) was given to a family of 
polypeptides (3). Two different IL-1 molecules were cloned, an acidic 
form (IL-1 tx; isoelectric focussing point pi 5)(4), and a neutral form (IL- 
1B; pi 7)(5). Although IL-1 a and IL-113 share biological activities, they are 
different proteins transcribed and translated from two different genes 
with an amino acid homology of only 26%. Several studies indicate that IL- 
113 predominates at the RNA level and that expression of lL-1a can be two 
orders of magnitude less than IL-113. In fact, in some cells, gene 
expression of IL-1 a requires protein synthesis inhibitors. Biological 
assays using non cross-reacting anti-human IL-1a and IL-1 B antibodies 
indicate that the B-form is the predominant IL-1 in humans (6). However, 
in order to better understand the role of the two IL-1's in various diseases 
it is necessary to quantitatively differentiate the amount of IL-1 a and IL- 
113 produced by mononuclear phagocytes. A radioimmunoassay (RIA) for IL- 
113 has been reported (7). We here report the development and use of a 
highly specific and sensitive radioimmunoassay for IL-1 a. A rabbit anti­
human recombinant IL-1a(hrlL-1a) antiserum was used. This antiserum 
does not cross-react with hrlL-1B (8). The sensitivity of the assay is 25- 
50 pg/ml hrlL-1a with a confidence limit of 95%.
MATERIALS AND METHODS
Preparation of rabbit anti-human recombinant IL-1 a (hrlL-1 cd antiserum. 
New Zealand white rabbits were immunized with 100 jug (hrlL-1a) in 
complete Freund’s adjuvant. Rabbits received booster immunizations in 
incomplete Freund's adjuvant every 4 weeks. hrlL-1 cx used in these studies 
was obtained from 4 sources: Genzyme Corp., Boston, MA; Danippon Co., 
Osaka, Japan; Hofmann-LaRoche, Nutley, NJ and Biogen, Geneva,
Switzerland. After 29 weeks the animals were bled and the serum was 
used. This antiserum did not crossreact with hrlL-1 ß (Cistron Technology 
Inc., Pine Brook, NJ), interleukin-2 (Cetus Corp., Emoryville, CA), TNF 
(Genentech Inc., South San Francisco, CA), hr-a-interferon, hr-y-interferon 
(both from Schering Corp., Kenilworth, NJ), hr-granulocyte-macrophage 
colony stimulating factor (Genetics institute, Cambridge, MA) or 
complement component C5a des arg (kindly provided by Dr. K. B. Yancey, 
Uniformed Services University of the Health Sciences, Bethesda, MD).
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Fractions
Figure 1. G-50 gel-filtration of labeled hrlL-1a. An aliquot from each 
fraction was incubated with rabbit anti-human IL-1a and then 
precipitated with goat anti-rabbit IgG. Open squares represent cpm's in 5 
|j,l of each fraction. Black diamonds represent the cpm's of each fraction 
which were precipitated by anti IL-1a antiserum.
lfldination and purification of labeled hrlL-1«. hrlL-1a was labeled by the 
chloramine T method (9). 5 p.g hrlL-1a and 0.5 mCi 125lodine (100 mCi/ml, 
New England Nuclear) were added to 10 jj.I 0.5 M sodium phosphate buffer 
(pH 7.4) and mixed. 10 (ig chloramine T (Sigma) were added and manually 
mixed for exactly 20-30 seconds. The reaction was terminated by adding 
100 (ig of the reducing agent sodium metabisulflte (Sigma).
The 125l IL-1a sample was chromatographed on a Sephadex G50 column (1 
x 30 cm) equilibrated and run in BSA buffer (0.25% bovine serum albumin, 
BSA, Sigma) in 0.01 M phosphate buffered saline containing 0.05% sodium 
azide) to separate bound from unbound 1251. BSA-buffer was used to 
equilibrate the column and to run the sample. 25 fractions (0.7 ml) were 
collected and counted in a gamma counter. Two peaks of 125l activity were 
detected (Fig. 1). The first peak contains the 125l labeled IL-1a and the 
second peak the free iodine. A volume of each fraction containing 
approximately 25,000 cpm was incubated with an excess amount of rabbit 
anti-hrlL-1a antiserum to determine the percentage of specific binding to 
the antiserum. After 24 hours, each fraction was precipitated with sheep 
anti-rabbit IgG (Sigma) in 6% polyethylene glycol. Fractions in which the 
antiserum precipitated more than 85% of the total counts were pooled 
(Fig. 1). The specific activity following each labelling procedure ranged 
from 15 to 30 jj-Ci/^ig. To confirm the homogeneity of 125] |L-1a, SDS- 
polyacrylamide gel electrophoresis and autoradiography were performed 
(Fig. 2).
Anti hrlL-1a antiserum titration. Samples containing approximately 
15,000 cpm of 1251 IL-1a in 100 p.! BSA-buffer were incubated for 18 
hours at room temperature with serial dilutions of rabbit anti hrlL-1a
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Figure 2. Homogeneity of 125|L-1 ot : Sodium-dodecyl-sulfate 
polyacrylamide gel-eiectrophoresis (15%) of the pooled fractions of 
125IL-1a shown in Fig. 1.
antiserum followed by precipitation with sheep anti-rabbit antiserum. Fig.
3 shows the titration curve, The 1:25,600 dilution of anti IL-1 cx antiserum 
bound 45% of the total cpm present in the incubation. We used a 1:22,500 
dilution of the anti IL-1a antiserum in the RIA.
AB dilutions
Figure 3. Rabbit anti human IL-1 a anti serum titration curve. Data points 
represent the amount of 125l IL-1 a precipitated by anti IL-1 a. Results are 
expressed in per cent of total cpm.
BlA-for hrlL-1 cx, Ail standards and samples were assayed in duplicates in 
10 x 75 mm polystyrene tubes. Eleven standards of hrlL-1a containing 10,
5, 2.5, 1.25, 0.625, 0.313, 0.156, 0.078, 0.039, 0.020 and zero ng/ml were 
measured in each assay. On day 1, 100 \x\ of standards in BSA-buffer, 
heparinized plasma, or urine and 100 |oJ of samples were incubated with
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100 |il of 1:22,500 dilution of anti IL-1 a. antiserum in BSA-buffer. Each 
tube also contained 300 jxl of BSA-buffer containing 0.3% heat- 
inactivated normal rabbit serum (NRS). This mixture was vortexed and 
incubated for 18 hours at room temperature. On day 2, 100 jil of 125l IL- 
1a solution containing approximately 10,000 cpm were added to each 
sample, the mixtures were vortexed and incubated another 24 hours at 
room temperature. On day 3, 700 \x\ of BSA-buffer containing 9% 
polyethylene glycol and a 1:70 dilution of sheep anti-rabbit IgG (Sigma) 
were added. The samples were vortexed and centrifuged at 1500 g for 15 
min in room temperature. Thereafter, the fluid phase of each sample was 
decanted, the tubes were kept inverted for 15 min and drained on 
absorbent paper. Samples were counted in a gamma counter. The mean of 
duplicates was calculated and the value for non-specific binding (without 
anti IL-1 a antiserum) was subtracted. The binding percentage was 
converted using the logit transformation (logit x = In [x/(100 - x)]). The 
logit values on the x axis were plotted against the standard 
concentrations of IL-1 a in pg/ml on the logarithmic y axis (Fig. 4); cpm 
from unknown samples were equally transformed and IL-1 a concentration 
was read off the standard curve. Values < 95% zero standard (logit x < 
2.94) were accepted, corresponding to 25-50 pg/ml hrlL-1a.
logit
Figure 4. Logit plot of hrlL-1 tx in either BSA-buffer, human plasma or 
urine. The line indicates the sensitivity of the RIA at the 95% confidence 
level (logit 2.94).
Preparation and incubation of human mononuclear cells (MNC). Heparinized 
donor blood (10 U/ml) was diluted 1:3 in 0.15 M saline and MNC were 
separated on Ficoll-Hypaque density gradients. MNC were washed three 
times in saline and suspended in ultrafiltered (10) RPMI 1640 
supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 jig/ml 
streptomycin and 10 mM HEPES (all from Microbiological Ass.,'
Walkersville, MD) containing 2% heat inactivated AB serum. 100 jj .I of MNC 
(5 x 106 cells/ml) were added to flat-bottom microtiter plates (A/S Nunc, 
Roskilde, Denmark). An equal volume of endotoxin (from E. coii B:55,
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Sigma) at various concentrations was added in serum-free RPMI. After 18 
hours incubation at 37 C in humidified air with 5% CO2 plates were 
exposed to 3 freeze-thaw cycles. The samples, containing both cell 
lysates and supernatants were centrifuged for 1 min at 13,000 g and the 
supernatants were frozen at -70 C until assayed.
Spiking of fresh human blood with monocvte supernatants. Human MNC 
were separated as described above and incubated in glass bottles at
4 x105 cells/cm2 for 1.5 hours at 37 C. The bottles were shaken, non­
adherent cells were decanted and replaced by 20 ml of fresh tissue 
culture medium containing 1% fresh human AB serum and heat-killed 
Staphylococcus epidermidis at a bacteria/MNC ratio of 10:1. Cells were 
incubated for 36 hours at 37 C and the supernatants obtained after 
centrifugation at 5,000 g for 30 min. The crude supernatant was used to 
spike freshly obtained heparinized blood or urine. Spiked blood and urine 
samples were incubated for 2 hours at 37 C on a rotating rack, centrifuged 
for 10 min at 1500 g and supernatants were assayed for IL-1a and 1L-1B 
in the specific RIA's. As a control, the crude preparation was incubated for 
2 hours in RPMI. After incubation all samples were diluted 5- and 50-fold 
in BSA-buffer and assayed.
RESULTS
Recovery of human monocvte derived IL-1 from urine and plasma. When 
corrected for the dilution factor, the original preparation of crude 
monocyte supernatant used in these experiments contained 15 ng/ml IL- 
13 and 4 ng/ml IL-1 a (left hand side of Fig. 5). 100% of both IL-1 a and IL- 
13 were recovered in the urine samples (middle part of Fig. 5). In 
contrast, when heparinized blood was spiked and plasma tested for IL-1,
MNC derived iL-1 in: RPMI urine plasma
Figure 5. Recovery of monocyte-derived IL-1 a and IL-13 following 
incubation in human blood or urine. Dilutions are indicated on the 
horizontal axis. The ng/ml of either IL-1a or IL-1B are indicated on the 
vertical axis.
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100% of 11-1 a was recovered but only 50% of IL-13. Similar results were 
obtained in blood and urine from 3 human subjects.
Production of IL-1g from MNC of 8 human subjects. We obtained blood 
from 8 human subjects and stimulated the MNC with various 
concentrations of endotoxin during a single day. After 24 hours, IL-1a 
production (extracellular and cell-associated) was assayed in a single 
RIA. As shown In Fig. 6, there was no detectable IL-1 a in the RPMI medium 
control (all donors MNC produced amounts of IL-1 ex less than the detection 
limit (50 pg/ml). In seven of the eight donors, MNC IL-1 a production was 
elevated when a concentration of 5 ng/ml was employed. The amount of 
IL-1 a increased with higher concentrations of endotoxin in six of the eight 
donors; however, in two donors, there was clearly less IL-produced at 5,
50 and even 500 ng/ml of endotoxin.
Total IL-1 alpha (secreted plus cell-associated)
Medium 0.5 ng/ml 5 ng/ml 50 ng/ml 500 ng/ml 
endotoxin
Figure 6. IL-1 a levels measured in the MNC of eight human subjects 
incubated with endotoxin for 24 hours. Total IL-1a (extracellular and cell- 
associated) is shown on the vertical axis.
DISCUSSION
In the present study, we report a sensitive and specific RIA for human 
IL-1 a. This assay detects 25-50 pg/ml IL-1 ot, in BSA buffer or tissue 
culture medium and the binding of labeled IL-1 a in this RIA was not 
influenced by the presence of a variety of unlabeled human cytokines. The 
detection of human recombinant human IL-1 a is also not significantly 
influenced by normal human heparinized plasma or freshly voided urine 
since we observed nearly identical standard curves when the recombinant 
IL-1 a was diluted in plasma, urine, or BSA buffer. We also examined the 
recovery of natural IL-1 a present in crude human monocyte supernates.
The recovery of natural IL-13 from freshly obtained human heparinized 
blood was only 50%, unlike the 100% recovery of IL-1 a. These results 
support the concept that the IL-13 molecule itself seems to be more
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vulnerable to the action of unidentified agents present in plasma than 
IL-1 a.
We used the RIA to measure the amount of IL-1 a produced by human MNC in 
vitro. We employed endotoxin as a stimulant and measured the total IL-1 a 
content of the incubation mixture. In all donors, the MNC did not produce 
detectable levels of IL-1 a when cultured in RPMI which had been subjected 
to ultrafiltration to remove small amounts of endotoxins which often 
contaminate tissue culture media. We also used a single source of human 
AB serum which we prepared with pyrogen-free conditions. Therefore, we 
believe that under these conditions, human blood MNC do not produce more 
than 50 pg/ml of IL-1 a. This methodology could be used to study the 
"spontaneous" production of IL-1 a In human subjects with various 
diseases or undergoing physiologic stresses.
The production of IL-1 a was observed in 3 donors at the lowest 
concentration of endotoxin tested (0.5 ng/m) and Increased in all donors in 
a dose-response fashion. However, two of the eight donors showed 
markedly less IL-1 a at the higher concentrations of endotoxin. Since the 
stimulation and RIA were performed on all samples at one time, these 
results do not reflect differences in the preparation of the MNC, the 
potency of the endotoxin, nor the sensitivity of the RIA. One interpretation 
is that some human subjects are low responders to endotoxin. Since we do 
not have data on the 1L-1I3 levels in these individuals, we cannot ascertain 
whether these donors also produce proportionately less IL-1 B. Studies 
relevant to this question are currently under investigation.
In the present studies, we measured both cell-associated as well as 
extracellular lL-1a. Since a considerable amount of IL-1 remains cell- 
associated following stimulation with endotoxin (11), we measured total 
IL-1 a. We did not separate the membrane fraction from the cytosolic 
compartment using ultracentrifugation in these studies and so the precise 
location of the IL-1 a remains unclear. There has been evidence that both 
forms of IL-1 can be isolated or visualized on human monocyte plasma 
membranes (12, 13). Mouse peritoneal macrophage membranes contain 
membrane IL-1 a (14, 15) but since there are no available antibodies to 
mouse IL-1 (3, it is unknown whether this form of IL-1 also exists on 
mouse cells.
Although the amount of IL-1 a produced by the MNC of the eight human 
subjects in the present study are lower than those reported from this 
laboratory for IL-1 3 (7), we cannot make any conclusions since these 
samples were not assayed for IL-13. Nevertheless, it appears that 
approximately 10-fold greater endotoxin is required to induce the 
production of comparable amount of IL-1 a. If these findings are confirmed 
in subsequent studies, then the amount of IL-1 a produced from human MNC 
may be greater than one would predict knowing the paucity of IL-1 a mRNA 
in human MC stimulated with endotoxin in vitro (6). It may be possible to 
speculate at this time that gene expression is not linked to translation in
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IL -1 cx as it is in IL-10. Alternatively, translation of JL-1 tx may be 
dependent on endotoxin concentrations different from that of IL-113. 
Finally, the differential stability of IL-1a compared to that of IL-13, 
demonstrated in this paper, may also contribute to the amount of IL-1a 
measured by RIA compared to IL-1 3. These and similar questions can now 
be studied employing the RIA for IL-1 a.
REFERENCES
1. Dinarello, C.A.: The Year in Immunology 2: 68 (1986).
2. Dinarello, C.A.: Rev. Infect. Dis. 6: 51 (1984).
3. Aarden, L.A., T.K. Brunner, J.C. Cerottini, et al.: J. Immunol.123: 2928 
(1979).
4. Lomedico, P.T., U. Gubler, C.P. Heilman, et al: Nature (London) 312: 458 
(1984).
5. Auron, P.E., A.C. Webb, L.J. Rosenwasser, S.F. Mucci, A. Rich, S.M. Wolff, 
and C.A. Dinarello: Proc. Natl. Acad. Sei. (USA) 81: 7909 (1984).
6. Demczuk, S., B. Mach and J.M. Dayer: mRNA levels to human IL-1 alpha 
and IL-1 beta in human monocytes. J. Cell. Mol. Immunol, in press (1988).
7. Lisi, P.J., C.W. Chu, G.A. Koch, S. Endres, G. Lonnemann and C.A. Dinarello: 
Lymphokine Res. 6:229 (1987)
8. Dinarello, C.A., T. Ikejima, S.J.C. Warner, S.F. Orencole, G. Lonnemann, J.G. 
Cannon and P. Libby: J. Immunol. 139:1902 (1987).
9. Hunter, W.M., and F.C. Greenwood: Nature 194; 495 (1962).
10. Dinarello, C.A., G. Lonnemann, R. Maxwell and S. Shaldon: J. Clin. 
Microbiol. 25:1233 (1987).
11. Lepe-Zuniga, J. L., J.S. Zigler, M.L. Zimmermann and I. Gery: Mol. 
Immunol. 22:1387 (1985).
12. Bayne, E.K., E. A. Rupp, G. Limjuco, J. Chin and J.A. Schmidt: J. Exp. Med. 
163:1267 (1986).
13. Conlon, P.J., K.H. Grabstein, A. Alpert, K.S. Prickett, T.P. Hopp and S. 
Gillis: J. Immunol. 139:98 (1987).
14. Kurt-Jones, E.A., D.T. Beller, S.B. Mizel and E.R. Unanue: Proc. Natl. Acad. 
Sei. USA 82:1204 (1985).
83
15. Beuscher, H. U., R. J. Fallon and H. R. Colten: J. Immunol. 139:1896 
(1987 ).
Send reprint requests to: Charles A. Dinarello M.D.
Division of Geographie Medicine 
and Infectious Diseases 
New England Medical Center 
750 Washington St.
Boston, MA 02111
84
